Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$13.37MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Jason A. Okazaki
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 73
- Beta
- 1.13
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 8.60
Financials
Revenue
$13.37M+1854.2%Net Income
$-3.86MEBITDA
$-3.84MFree Cash Flow
$-15.49MEPS (diluted)
$-0.20Shares Outstanding (diluted)
18.85M+994.2%Operating Expenses
$19.72MCash & Debt
$320.36MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $72.30M | $-6.12M | $-0.55 |
| 2024 | $28.52M | $-40.18M | $-6.69 |
| 2023 | $7.16M | $-61.23M | $-13.38 |
| 2022 | $0.00 | $-93.09M | $-22.82 |
| 2021 | $6.25M | $-129.85M | $-36.00 |
| 2020 | $79.11M | $-62.15M | $-15.00 |
| 2019 | $15.96M | $-97.63M | $-27.80 |
| 2018 | $14.80M | $-90.75M | $-39.80 |
| 2017 | $9.02M | $-42.81M | $-24.10 |
| 2016 | $0.00 | $-44.26M | $-25.70 |
| 2015 | $0.00 | $-28.45M | $-18.10 |
| 2014 | $0.00 | $-23.79M | $-34.00 |
| 2013 | $0.00 | $-19.40M | $-50.00 |
| 2012 | $0.00 | $-24.79M | $-97.40 |
Valuation
ASMBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
170+200.00%Social Signal Score
Mentions (12)
- Newszacks.com·18d ago·Positive
Best Momentum Stocks to Buy for September 17th MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.
View source ↗ - Newszacks.com·19d ago·Positive
New Strong Buy Stocks for September 17th MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.
View source ↗ - Newszacks.com·26d ago·Neutral
Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program – Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –
View source ↗ - Newszacks.com·28d ago·Neutral
Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newszacks.com·31d ago·Positive
Should You Buy Assembly Biosciences (ASMB) After Golden Cross? Assembly Biosciences, Inc. (ASMB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ASMB's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
View source ↗ - Newszacks.com·31d ago·Positive
5 Stocks With Recent Price Strength Buoyed by a Strong August EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.
View source ↗ - Newszacks.com·42d ago·Positive
New Strong Buy Stocks for August 25th IA, ASMB, LQDT, OFG and TGT have been added to the Zacks Rank #1 (Strong Buy) List on August 25th, 2026.
View source ↗ - Newszacks.com·45d ago·Positive
Best Momentum Stocks to Buy for August 21st LITE, ONTO and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 21st, 2026.
View source ↗ - Newszacks.com·46d ago·Positive
New Strong Buy Stocks for August 21st MCY, ASMB, ONTO, BSET and UNH have been added to the Zacks Rank #1 (Strong Buy) List on August 21st, 2026.
View source ↗ - Newsseekingalpha.com·51d ago·Positive
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal Assembly Biosciences is maintained at a 'Buy' rating, driven by pipeline advancement and a strong cash position. Key catalysts include phase 2 trials for GS-1179 in genital herpes and ABI-6250 in chronic HDV, PBC, and PSC, with multiple readouts expected 2027–2028. ASMB's partnership with Gilead on GS-1179 offers strategic optionality between milestone/royalty payments or a 40% cost-profit share.
View source ↗ - Newszacks.com·53d ago·Neutral
Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates Assembly Biosciences (ASMB) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $1.33 per share a year ago.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.66 per share
Typical surprise +26.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.20 vs $-0.72beat
- Thu, May 7$-0.54 vs $-0.73beat
- Thu, Mar 19$2.48 vs $-0.51beat
- Mon, Nov 10$-0.72 vs $-0.50miss
- Wed, Aug 6$-1.33 vs $-0.65miss
- Thu, May 8$-1.17 vs $-2.01beat
Estimates and results for ASMB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ASMB officers and directors.
- Bought
- $74.2m
- Sold
- $170k
17 trades
27 trades
- Bjorkquist Jeanette Msold
- Bjorkquist Jeanette Msold
- Bjorkquist Jeanette Msold
- White Nicole Ssold
- White Nicole Ssold
- Gilead Sciences, Inc.bought
- Gilead Sciences, Inc.bought
- Gilead Sciences, Inc.bought
56 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Feb 17, 2021 (44d later)Sell$1,001 - $15,000
- Chris Jacobshouse · NY27 · disclosed Feb 10, 2021 (44d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.